Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Baricitinib · Olumiant, LY-3009104

Small molecule · Inhibitor of Janus kinase 1 (JAK1), Janus kinase 2 (JAK2) and Tyrosine kinase 2 (TYK2) · developed by Eli Lilly And Co

Approved FDA, May 2018

LLY Developer

1 Registered trials

What is Baricitinib?

Baricitinib is an oral Janus kinase (JAK) inhibitor that blocks JAK enzymes, preventing phosphorylation and activation of STAT proteins in cytokine and growth factor signaling. It is studied in type 1 diabetes mellitus.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: Olumiant, LY-3009104, INCB-028050
Drug type: Small molecule
Targets: Janus kinase 1 (JAK1), Janus kinase 2 (JAK2), Tyrosine kinase 2 (TYK2), Janus kinase 3 (JAK3) (secondary target)
Mechanism: Inhibitor of Janus kinase 1 (JAK1), Janus kinase 2 (JAK2) and Tyrosine kinase 2 (TYK2)
Pathways: JAK/STAT signaling, cytokine signaling, hematopoiesis and immune cell function
Therapy area: Endocrine, Immunology
Developer: Eli Lilly And Co (LLY)
FDA status: Approved as Olumiant (May 31, 2018), NDA207924 · FDA label
UNII: ISP4442I3Y

✅ FDA-approved uses

Rheumatoid arthritis
COVID-19
Alopecia areata

From the indications section of the FDA label (version of Jun 30, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07222137	Phase 3	Diabetes Mellitus, Type 1	Recruiting	LLY

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Diabetes Mellitus, Type 1

Other drugs acting on JAK1 / JAK2 / TYK2

Deucravacitinib FDA approved Fedratinib FDA approved Upadacitinib FDA approved Filgotinib Phase 3 LY5830966 Phase 1

More from Eli Lilly And Co

Abemaciclib FDA approved Donanemab FDA approved Dulaglutide FDA approved Imlunestrant FDA approved Lebrikizumab FDA approved Mirikizumab FDA approved Orforglipron FDA approved Pirtobrutinib FDA approved Selpercatinib FDA approved Tirzepatide FDA approved Brenipatide Phase 3 Clazakizumab Phase 2

Sources

Updated Oct 11, 2026. Something wrong or missing? Report it on the LLY page.

Follow LLY, the company behind Baricitinib

See LLY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

LLY catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z